← Back to Search

Mucolytic Agent

NAC for COVID-19 (NACinCOVID2 Trial)

Phase 2
Waitlist Available
Research Sponsored by Cambridge Health Alliance
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks starting the day after enrollment

Summary

This trial is testing if taking an NAC supplement can make COVID-19 symptoms less severe and shorter in adults who have tested positive but are not hospitalized.

Who is the study for?
This trial is for individuals who have tested positive for COVID-19 within the past 7 days. It's not suitable for pregnant women or those already hospitalized due to COVID.
What is being tested?
The study aims to see if taking N-acetylcysteine (NAC) orally can reduce the severity and length of COVID-19 symptoms compared to a placebo, which has no active ingredients.
What are the potential side effects?
Possible side effects of NAC may include nausea, vomiting, rash, and headache. The placebo is unlikely to cause any direct side effects since it doesn't contain an active drug.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks starting the day after enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks starting the day after enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Symptom duration
Symptom severity
Secondary study objectives
Need for higher level of care/hospitalization

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NACExperimental Treatment1 Intervention
Group receiving intervention/study drug NAC
Group II: PlaceboPlacebo Group1 Intervention
Group receiving placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
N-acetylcysteine
2008
Completed Phase 4
~1290

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
N-acetylcysteine (NAC) works primarily as an antioxidant and a precursor to glutathione, a critical molecule in the body's defense against oxidative stress. By replenishing glutathione levels, NAC helps reduce oxidative damage and inflammation, which are significant contributors to the severity of COVID-19. This mechanism is crucial for COVID-19 patients because the virus can induce a hyperinflammatory state and oxidative stress, leading to severe respiratory and systemic complications. Other treatments with similar antioxidant and anti-inflammatory properties aim to mitigate these effects, thereby potentially reducing the severity and duration of symptoms.
Participation of nitrogen oxide and its metabolites in the genesis of hyperimmune inflammation in COVID-19.Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19.Reaction Cycles of Halogen Species in the Immune Defense: Implications for Human Health and Diseases and the Pathology and Treatment of COVID-19.

Find a Location

Who is running the clinical trial?

AlturixUNKNOWN
The Thoracic FoundationUNKNOWN
Cambridge Health AllianceLead Sponsor
62 Previous Clinical Trials
22,409 Total Patients Enrolled

Media Library

N-acetylcysteine (Mucolytic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05074121 — Phase 2
Coronavirus Research Study Groups: Placebo, NAC
Coronavirus Clinical Trial 2023: N-acetylcysteine Highlights & Side Effects. Trial Name: NCT05074121 — Phase 2
N-acetylcysteine (Mucolytic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05074121 — Phase 2
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top